IMA Advisory Services Inc. Lowers Stock Position in Repligen Corporation $RGEN

IMA Advisory Services Inc. decreased its holdings in Repligen Corporation (NASDAQ:RGEN) by 90.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 730 shares of the biotechnology company’s stock after selling 6,862 shares during the quarter. IMA Advisory Services Inc.’s holdings in Repligen were worth $98,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Hantz Financial Services Inc. increased its stake in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. CWM LLC increased its position in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares during the period. Center for Financial Planning Inc. raised its stake in Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 126 shares during the last quarter. Trust Co. of Vermont acquired a new stake in Repligen during the 3rd quarter worth approximately $67,000. Finally, Wilmington Savings Fund Society FSB lifted its position in Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 495 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on RGEN shares. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Canaccord Genuity Group boosted their price objective on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. Wells Fargo & Company upped their price objective on shares of Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Finally, Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $177.92.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO James Bylund sold 2,191 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 4,657 shares of company stock worth $706,877. Insiders own 1.20% of the company’s stock.

Repligen Trading Up 2.9%

Shares of RGEN opened at $136.44 on Friday. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $175.77. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.68 billion, a P/E ratio of 6,825.41, a PEG ratio of 2.42 and a beta of 1.13. The firm’s 50-day moving average is $159.23 and its two-hundred day moving average is $145.53.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.